Back

Ready for prime time as first-line therapy ? Introduction.

30 April 2017 (16:31 - 16:40)
Organised by:
Congress Presentation Part of: The Grand Debate 1: Neprilysin inhibitor - Vasodilators - LCZ 696 (Sacubitril/Valsartan) Diuretics HFA Premium Access Heart Failure 2017 - 4th World Congress on Acute Heart Failure

About the speaker

Photo
Professor Eugene Braunwald

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

5 More presentations in this session

Presentation thumbnail
Professor J. McMurray (Glasgow, GB)
Slides Video
Presentation thumbnail
Professor M. Jessup (Dallas, US)
Slides Video
Presentation thumbnail
Video
Presentation thumbnail
Video
Presentation thumbnail
Slides Video

Access the full session

Session thumbnail
The Grand Debate 1: Neprilysin inhibitor - Vasodilators - LCZ 696 (Sacubitril/Valsartan)

The Event

Event poster

Heart Failure 2017 - 4th World Congress on Acute Heart Failure

30 April 2017 16:31 CET
You may be interested in
thumbnail
Congress Presentation
Conclusion.
28 August 2022
thumbnail
Congress Presentation
Efficacy and safety of catheter ablation for paroxysmal atrial fibrillation as first-line therapy vs. after drug failure -analysis from Japan Nationwide Ablation (J-AB) Registry-
2 September 2024
thumbnail
Congress Presentation
Only 1 in 5 european HF centres "always" initiate all four GDMT pillars during hospitalisation despite near-universal IV iron and uptitration capacity
30 August 2026
thumbnail
Congress Presentation
Diagnosis and management of acute and subacute CVDs in patients with active cancer.
27 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources